ISB News

ISB’s Cancer Genomics Cloud Team Launches BigQuery Platform

Genomeweb published an article on the Cancer Genomics Cloud pilots. Learn more about ISB’s CGC project.

PDF: Cancer Genomics Cloud Pilot Developers Provide Update, Open Up Platforms for Early Testing | GenomeWeb

NEW YORK (GenomeWeb) – The developers of the three proposals selected by the National Cancer Institute for the Cancer Genomics Cloud pilots — an effort to build sustainable computing infrastructure for analyzing omics data from the Cancer Genome Atlas and other NCI-funded projects — have begun various stages of testing ahead of the nine-month evaluation phase of the initiative, which is slated to begin in January 2016 when the first versions of all three platforms will be made available.

The proposals selected for the NCI initiative include one from Seven Bridges Genomics; one from the Institute for System Biology working in collaboration with Google and SRA International; and one from the Broad Institute in partnership with University of California, Berkeley and UC Santa Cruz.

Recent Articles

  • Dr. Sean Gibbons Promoted to Associate Professor

    Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…

  • AmeriCorps Member Sara Calder Joins ISB as Systems Health and STEM Coordinator

    Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.

  • In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

    Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.